TherapeuticsMD
TXMD
$1.86
Share price
-0.53%
Change (1 day)
-48.76%
Change (1 year)
Categories
P/S ratio for TherapeuticsMD (TXMD)
P/S ratio as of April 2024 (TTM): 11.0
According to TherapeuticsMD's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 11.0479. At the end of 2023 the company had a P/S ratio of 16.4.
P/S ratio history for TherapeuticsMD from 2003 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 16.4 | -21.19% |
| 2022 | 20.8 | 1095.03% |
| 2021 | 1.74 | -68.93% |
| 2020 | 5.59 | -57.7% |
| 2019 | 13.2 | -76.77% |
| 2018 | 56.9 | -26.96% |
| 2017 | 77.9 | 32.96% |
| 2016 | 58.6 | -36.03% |
| 2015 | 91.6 | 98.15% |
| 2014 | 46.2 | -46.29% |
| 2013 | 86.1 | 6.24% |
| 2012 | 81.0 | 140.77% |
| 2011 | 33.7 | 33.35% |
| 2010 | 25.2 | -98.7% |
| 2009 | > 1000 | |
| 2007 | 1.04 | -5.55% |
| 2006 | 1.10 | 23.22% |
| 2005 | 0.8899 | -1.69% |
| 2004 | 0.9052 | -36.48% |
| 2003 | 1.43 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.46 | -77.75% | 🇺🇸 USA |
 AbbVie ABBV | 5.20 | -52.90% | 🇺🇸 USA |
 Agile Therapeutics
AGRX | 0.1400 | -98.73% | 🇺🇸 USA |
 Royalty Pharma RPRX | 7.10 | -35.69% | 🇬🇧 UK |
 Lannett Company LCI | 0.0238 | -99.78% | 🇺🇸 USA |